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Background: Adverse drug reactions (ADR) are a major clinical problem accounting
for significant hospital admission rates, morbidity, mortality, and health care costs.
One-third of people with diabetes experience at least one ADR. However, there is notable
interindividual heterogeneity resulting in patient harm and unnecessary medical costs.
Genomics is at the forefront of research to understand interindividual variability, and there
are many genotype-drug response associations in diabetes with inconsistent findings.
Here, we conducted a systematic review to comprehensively examine and synthesize
the effect of genetic polymorphisms on the incidence of ADRs of oral glucose-lowering
drugs in people with type 2 diabetes.
Methods: A literature search was made to identify articles that included specific
results of research on genetic polymorphism and adverse effects associated with
oral glucose-lowering drugs. The electronic search was carried out on 3rd October
2020, through Cochrane Library, PubMed, and Web of Science using keywords and
MeSH terms.
Result: Eighteen articles consisting of 10, 383 subjects were included in this review.
Carriers of reduced-function alleles of organic cation transporter 1 (OCT 1, encoded by
SLC22A1) or reduced expression alleles of plasma membrane monoamine transporter
(PMAT, encoded by SLC29A4) or serotonin transporter (SERT, encoded by SLC6A4)
were associated with increased incidence of metformin-related gastrointestinal (GI)
adverse effects. These effects were shown to exacerbate by concomitant treatment
with gut transporter inhibiting drugs. The CYP2C9 alleles, ∗2 (rs1799853C>T) and
∗3 (rs1057910A>C) that are predictive of low enzyme activity were more common in
subjects who experienced hypoglycemia after treatment with sulfonylureas. However,
there was no significant association between sulfonylurea-related hypoglycemia and
genetic variants in the ATP-binding cassette transporter sub-family C member 8
(ABCC8)/Potassium Inwardly Rectifying Channel Subfamily J Member 11 (KCNJ11).
Compared to the wild type, the low enzyme activity C allele at CYP2C8∗3
(rs1057910A>C) was associated with less weight gain whereas the C allele at
rs6123045 in the NFATC2 gene was significantly associated with edema from
rosiglitazone treatment.
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Conclusion: In spite of limited studies investigating genetics and ADR in diabetes, some
convincing results are emerging. Genetic variants in genes encoding drug transporters
and metabolizing enzymes are implicated in metformin-related GI adverse effects, and
sulfonylurea-induced hypoglycemia, respectively. Further studies to investigate newer
antidiabetic drugs such as DPP-4i, GLP-1RA, and SGLT2i are warranted. In addition,
pharmacogenetic studies that account for race and ethnic differences are required.
Keywords: pharmacogenomics, type 2 diabetes, adverse drug outcomes, oral glucose-lowering drugs,
gastrointestinal side effects, hypoglycemia, weight gain
INTRODUCTION
Diabetes mellitus refers to a group of metabolic disorders
characterized by hyperglycemia resulting from insufficient
production and/or ineffective response of cells to insulin. It
is one of the major contributors to morbidity and mortality
globally, and its prevalence continues to rise. By 2019, an
estimated 463 million adults aged 20–79 years were living with
diabetes which accounts 9.3% of the global population in this
age group (International Diabetes Federation, 2019). This figure
is expected to surge to 578 million (10.2%) by 2030 and to 700
million (10.9%) by 2045, most of this in the form of type 2
diabetes (T2D) (International Diabetes Federation, 2019). Poorly
controlled diabetes progressively leads to chronic microvascular,
macrovascular and neuropathic complications which manifest as
renal failure, blindness, lower limb amputation, and accelerated
vascular disease.
Several drugs are available for the management of T2D,
referred to as glucose lowering agents. These include: biguanides
(metformin), insulin secretagogues (sulfonylureas, meglitinides),
thiazolidinediones, alpha glucosidase inhibitors (acarbose),
incretin mimetics (GLP-1RAs, DPP-4is), amylin antagonists,
sodium-glucose co-transporter-2 inhibitors (SGLT-2i), and
insulin. These classes of drugs are either prescribed as
monotherapy or given in combination.
The management of T2D is guided by national and
international evidence-based guidelines (Buse et al., 2020),
but there is noticeable inter-individual variability in treatment
response as defined by glycemic reduction and adverse drug
reactions. This variation is the net effect of several environmental
and clinical factors including age, sex, adherence, concomitant
therapy, drug interactions, and disease severity. In addition to
these, a patient’s genotype can affect interindividual differences
in drug response.
Adverse drug reactions are major clinical and public health
problems world-wide. In the UK, around 6.5% of hospital
admissions are due to adverse drug reactions (Pirmohamed et al.,
2004), and that almost 15% of patients experience an ADR during
their admission (Davies et al., 2009, 2010). The projected annual
cost of such admissions to the NHS was £466m (Davies et al.,
2009). Glucose lowering agents are one of the drugs of great
concern for ADRs (Ducoffe et al., 2016). They have a well-
described set of ADRs that are detrimental to individuals’ health
and quality of life (Table 1). In the US, from 2010 to 2013, there
were 600,991 ADRs associated with glucose-lowering agents with
an average hospital marginal cost of $4, 312 resulting in an annual
hospital cost of $2.59 billion (Spector et al., 2017). Optimizing
drug therapy through the avoidance of ADRs will dramatically
improve patient health while generating millions of dollars by
saving unnecessary medical costs.
However, there is inter-individual variability in the type and
severity of ADRs experienced by individuals taking glucose-
lowering drugs. While clinical and environmental factors
influence this, genomic factors are also important. Here, we aim
to undertake a systematic review of pharmacogenomic studies of
ADRs related to oral glucose-lowering drugs.
METHODS
This systematic review is reported according to the Preferred
Reporting Items for the Systematic Reviews and Meta-analysis
Protocols (PRISMA-P) 2015 Checklist (Shamseer et al., 2015).
Type of Participants
Participants included in eligible studies must be diagnosed with
T2D and treated with oral glucose-lowering drugs.
Type of Exposure
We included studies in which participants genotype were
investigated in relation to ADRs of oral glucose-lowering agents.
Outcomes
The primary outcome was the incidence of any of the adverse
effects of glucose-lowering drugs (Table 1). For metformin,
GI adverse effects were considered - hypoglycemia and




Studies assessing the effect of genetic variations on the incidence
of adverse effects of oral glucose-lowering drugs in people with
T2D, published up to 3rd October 2020 in English language
without any geographical restriction were included in this review.
Exclusion Criteria
We did not consider news, qualitative studies, case reports,
reviews, editorials, and comments; and all non-published studies
and published in non-English languages. Studies in which
relevant data on genetic polymorphisms and/or ADRs associated
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TABLE 1 | List of adverse drug reactions related to glucose-lowering drugs in type 2 diabetes.
Drug Side effects Comments
Metformin GI side effects (10%−25%): nausea, indigestion, abdominal
cramp or bloating, or combination of these (Bailey and Turner,
1996; Goodman, 2017).
Decrease in vitamin B12 concentration (5 to 10%) (Bell, 2010;
de Jager et al., 2010; Aroda et al., 2016; Donnelly et al.,
2020)
Lactic acidosis (Misbin, 2004)
Symptoms are usually mild, transient, and reversible after
dose reduction. When severe requires drug switch in about
5% of the population.
Patient may develop anemia and/or peripheral neuropathy
(Bell, 2010).
Rare but serious
Thiazolidinediones Increased risk of overweight, congestion, heart failure,
fractures, bladder cancer (pioglitazone) and myocardial
infarction (rosiglitazone) (Jearath et al., 2016).
An average of 2 to 4 kg weight gain in the first year of
treatment (Yki-Järvinen, 2004; Winkelmayer et al., 2008).
Higher risk of adverse cardiovascular events with
rosiglitazone (Winkelmayer et al., 2008; Juurlink et al., 2009;
Graham et al., 2010).
Sulfonylurea and meglitinides Hypoglycemia including coma (Schopman et al., 2014).
Weight gain of 1–3 kg (Meneilly, 2011; Guardado-Mendoza
et al., 2013)
GLP-1 analogs Nausea and vomiting, injection site reactions Could be mediated through neural activation of specific CNS
neurons due to peripheral dosing of peptide (Madsbad et al.,
2011).
DPP-4 inhibitors Headache, nasopharyngitis, and urinary tract infections
(sitagliptin) (Katzung et al., 2019).
Have no effects on body weight or risk of hypoglycemia
(Salvo et al., 2016).
SGLT2 inhibitors Genital and urinary tract infections. IV volume depression and
hypotension can result from osmotic diuresis (Katzung et al.,
2019).
with oral glucose-lowering agents is lacking or impossible to
extract were also excluded.
Search Strategy for Identifying Relevant
Studies
A literature search was made to identify articles that included
specific results of research on genetic polymorphisms and
adverse effects associated with oral glucose-lowering agents. The
electronic search was carried out on 3rd October 2020, through
Cochrane Library, PubMed, and Web of Science using keywords
and MeSH terms with no restriction for time of publication. The
search strategy conducted in MEDLINE via PubMed, Cochrane,
and Web of Science is shown in Supplementary Material. We
also manually searched reference lists from relevant studies
and contact experts in the field in order to identify additional
eligible studies.
Selection of Studies for Inclusion in the
Review
Two review authors (AMB and AYD) independently identified
articles and then screened their titles and abstracts for eligibility.
Thereafter, full texts of articles considered to be eligible
were retrieved. Furthermore, the review authors independently
assessed the eligibility for inclusion in the review based on the
inclusion and exclusion criteria. Disagreements between the two
authors was resolved by consensus. A PRISMA flow diagram
(Shamseer et al., 2015) was employed to document the process
of literature selection and the reasons for exclusion of articles
were stated.
Data Extraction and Management
Two review authors (AMB and AYD) independently extracted
data from the articles reviewed. A data extraction form for this
purpose was designed. Data was collected on the first author’s
name, year of publication, geographical location (country where
the study was performed), sample size, population characteristics,
relevant genetic polymorphism, primary outcome measurements
(incidence of adverse events after treatment with oral glucose-
lowering agents). Any disagreements between the two review
authors were resolved through discussion and consensus.
Study characteristics and the effect estimates of genetic
polymorphisms on the incidence of adverse effects of oral
glucose-lowering agents was presented in full, in tabular form.




Of the 362 studies identified, 66 were included for review of the
full text. Of these studies, 18 studies met the inclusion criteria
(Figure 1).
Characteristics of Included Studies
Eighteen articles comprised of 10, 383 subjects were included
in this review (Table 2). Among these, two studies were
multinational (Bailey et al., 2010; Dawed et al., 2019). While 12
studies were conducted in Europe (Holstein et al., 2005, 2011,
2012; Ragia et al., 2009, 2012, 2014; Tarasova et al., 2012; Dujic
et al., 2015, 2016a,b, 2018; Dawed et al., 2016), three were in Asia
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FIGURE 1 | PRISMA flow diagram for search results October 30, 2020.
(Kahn et al., 2006; Sato et al., 2010; Gökalp et al., 2011) and one
was in the US (Ruaño et al., 2009).
Five of these studies comprising of 5,438 subjects were
conducted to investigate association between genetic
polymorphisms and metformin-related GI adverse effects
(Tarasova et al., 2012; Dujic et al., 2015, 2016a,b; Dawed et al.,
2019). Association between genetic polymorphisms and the risks
of sulfonylurea-induced hypoglycemia was evaluated in nine
studies comprising of 1,944 subjects (Holstein et al., 2005, 2011,
2012; Ragia et al., 2009, 2012, 2014; Sato et al., 2010; Gökalp et al.,
2011; Dujic et al., 2018). Among the sulfonylureas, glimepiride
was the most investigated (nine studies) (Holstein et al., 2005,
2012; Ragia et al., 2009, 2012, 2014; Sato et al., 2010; Gökalp
et al., 2011; Dujic et al., 2018) followed by gliclazide (Ragia
et al., 2009, 2012, 2014; Gökalp et al., 2011; Dujic et al., 2018)
(five studies) and glibenclamide (Holstein et al., 2005, 2011,
2012; Sato et al., 2010; Dujic et al., 2018) (five studies). Four
studies consisting of 3, 001 subjects evaluated the genetics of
thiazolidinediones-induced edema and weight gain (Kang et al.,
2006; Ruaño et al., 2009; Bailey et al., 2010; Dawed et al., 2016).
Metformin
Metformin is the first-line therapy for T2D. Around 30% of
metformin treated subjects experience gastrointestinal (GI) side
effects manifested as nausea, indigestion, abdominal cramps,
bloating, diarrhea, or combination of these (Table 1) (Garber
et al., 1997; Hirst J. A. et al., 2012). Metformin is an organic
cation, and carrier proteins mediate its oral absorption, hepatic
uptake, and renal elimination. Several solute carrier transporters,
expressed in the membranes of the enterocytes, could be
involved in the absorption of metformin from the intestinal
lumen, including organic cation transporter (OCT) 1, plasma
membrane monoamine transporter (PMAT), carnitine/cation
transporter 1, OCT3 (encoded by SLC22A3), and serotonin
reuptake transporter (SERT) (Han et al., 2015). Genetic variants
in genes encoding these transporters have been reported in five
articles (Table 3) (Tarasova et al., 2012; Dujic et al., 2015, 2016a,b;
Dawed et al., 2019).
Association between genetic variants in SLC22A1 (a gene
encoding OCT1), and GI intolerance related to metformin
therapy have been reported in three studies (Tarasova et al., 2012;
Dujic et al., 2015, 2016a). A study conducted using the GoDARTS
cohort (Hébert et al., 2018), in 251 metformin-intolerant and
1,915 metformin-tolerant individuals showed that the presence
of two or more reduced-function alleles at R61C, C88R, G401S,
M420del, or G465R increased the odds of GI side effects of
metformin by more than 2-fold (Dujic et al., 2015). This effect
was over 4-fold with concomitant use of OCT1-inhibiting drugs.
The findings were replicated in another prospective observational
cohort study from Bosnia and Herzegovina that included 92




































TABLE 2 | Description of included studies.
References Country Study drug Study period Parent study Population Gene Comparators N
Dawed et al. (2019) Multinational
(Europe)





Dujic et al. (2015) Scotland, UK Metformin 1 January 1994–1
June 2011.
GoDARTS White Europeans SLC22A1 metformin-intolerant 251
Metformin- tolerant 1,915
Dujic et al. (2016b) Scotland, UK Metformin 1 January 1994–1
June 2011.




Dujic et al. (2016a) Bosnia and
Herzegovina
Metformin T2D diagnosis











Gökalp et al. (2011) Turkey Glimepiride
Gliclazide
Glipizide
2003 and 2005 None Subjects with T2D
treated with SU for




























With severe hypoglycemia 102










With severe hypoglycemia 20





























































































TABLE 2 | Continued
References Country Study drug Study period Parent study Population Gene Comparators N




None Subjects with T2D
treated with Sus
ABCC8 Without hypoglycemia 32
With hypoglycemia 125





None Subjects with T2D
treated with SU
KCNJ11 Without hypoglycemia 84
With hypoglycemia 92





None Subjects with T2D
treated with SU
CYP2C9 Without hypoglycemia 84
With hypoglycemia 92





None Subjects with T2D
treated with SU
CYP2C9 Without hypoglycemia 84
With hypoglycemia 92









For BMI: ADORA1, PKM2,
ADIPOR2, UCP2, APOH,
IRS1, LIPA, RARB, and
CHRM3
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TABLE 3 | Association between metformin and selected SNPs for the incidence of GI adverse outcomes.
References Outcome
measure






Metformin 1,128 286 SLC29A4 rs3889348G>A The G allele at rs3889348 (SLC29A4)
was associated with higher odds of
gastrointestinal intolerance (OR 1.34
[1.09–1.65], P = 0.005).
Dujic et al. (2015) Incidence of GI
adverse effects





Compared to carriers of one or no
deficient allele, carriers of two
reduced-function OCT1 alleles had
higher odds of intolerance (OR 2.41
[1.48-3.93], P < 0.001).
Dujic et al. (2016b) Incidence of GI
adverse effects
Metformin 1,356 164 SLC6A4 L*L*
L*S*
S*S*
Each S* alleles was associated with
higher odds of metformin intolerance
(OR = 1.28 [1.01–1.63], P = 0.04).
Multiplicative interaction between






Dujic et al. (2016a) Incidence of GI
adverse effects
Metformin 49 43 SLC22A1 R61C
M420del
Each OCT1 reduced-function allele
was associated with higher odds of
GI side effects (OR = 2.31















Each A allele at rs628031 was
associated with lower odds of
intolerance (OR = 0.39 [0.19–0.82], P
= 0.01) Each 8 bp insertion at
rs36056065 was associated with
lower odds of intolerance (OR = 0.41
[0.23–0.72], P = 0.01)
newly diagnosed subjects in the first 6 months of metformin
treatment (Dujic et al., 2016a). Likewise, Tarasova et al. showed
significant associations between a SNP (rs628031) and an 8 bp
insertion (rs36056065) in the SLC22A1, with GI side effects of
metformin (Tarasova et al., 2012).
Dawed et al. reported association between rs3889348, a
variant that alters intestinal expression of the SLC9A4 (a gene
encoding PMAT), with metformin related GI intolerance in 286
severe intolerant and 1,128 tolerant subjects. The G allele that
reduces expression of SLC29A4 was associated with 34% higher
odds of intolerance. Concomitant administration of metformin
transporter inhibiting drugs exacerbate GI intolerance by more
than 3-folds (Dawed et al., 2019).
Considering involvement of serotonin reuptake transporter
(SERT) in metformin intestinal absorption, Dujic et al.
investigated association between the low-expressing S∗ allele
derived from a composite SERT (SLC6A4)-5-HTTLPR/rs25531
genotypes andmetformin intolerance. In this study, each S∗ allele
was associated with 30% higher odds of intolerance. Interestingly,
a multiplicative interaction between OCT1 and SERT genotypes
was observed (Dujic et al., 2016b). Carriers of reduced function
alleles in OCT1 at the background of the wild type SERT (L∗L∗)
genotype had greater odds of intolerance (OR 9.25 [3.18–27.0])
compared to carriers of the S∗ allele.
Sulfonylureas
Sulfonylureas were the first oral glucose-lowering therapy
introduced into clinical practice and along with metformin,
are the most prescribed drugs for the management of T2D
(Inzucchi et al., 2015). SU are transported into the liver by
OATP1B1 (encoded by SLCO1B1) andmetabolizedmainly by the
polymorphic CYP2C9 enzyme and to a lesser extent by CYP2C19
enzyme (Becker et al., 2008). CYP2C9∗2 (R144C, rs1799853)
and CYP2C9∗3 (I359L, rs1057910) are the two most common
variants that have been associated with poor metabolism of SU
(Semiz et al., 2010). Sulfonylureas induce glucose-independent
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TABLE 4 | Association between sulfonylureas and selected SNPs for the incidence of hypoglycemia.
References Outcome
measure





















observed (P = 0.035).




















The number of CYP2C9 deficient
alleles increased the odds of
hypoglycemia nearly 3-fold (OR,
2.81; 95% CI, 1.30-6.09;
P = 0.009) only at the POR*1/*1
genotype background
Statistically significant interaction
between POR and CYP2C9

















There was no overrepresentation
of the CYP2C9 *2/*2, *2/*3, and
*3/*3 variants in the SH group








337 20 CYP2C9 CYP2C9*1
CYP2C9*2
CYP2C9 *3
The CYP2C9 genotypes *3/*3
and *2/*3 that are predictive of
low enzyme activity were more
common in the hypoglycemic
group than in the comparison
groups (10 vs. <2%, OR 5.2;
95% CI, 1.01, 27).













ABCC8 Ser1369Ala Ser1369Ala variant in ABCC8
does not affect the response to
sulfonylurea treatment and so, is
not a major player in the etiology
of severe hypoglycemia.




32 125 ABCC8 Ser1369Ala No significant differences in the
distribution of the Ser1369Ala
genotype between patients with
or without severe hypoglycemia
(p = 0.26)






KCNJ11 E23K KCNJ11 E23K polymorphism
did not affect hypoglycemia risk.













POR*28 allele was not
associated with severe
hypoglycemia. CYP2C9 *2 allele
increased the risk of
hypoglycemia by more than 3
times (OR: 3.218, p = 0.031).
POR*28 allele is masking the
association of CYP2C9*2 allele
with severe hypoglycemia.









The presence of CYP2C9*3 allele
puts subjects with T2D at higher
risk of hypoglycemia when
receiving the SU
insulin release from the pancreatic β-cells by binding to the ATP-
sensitive potassium (KATP) channels, SUR1 and Kir6.2, that are
encoded by the ABCC8 and KCNJ11 genes, respectively.
Hypoglycemia is the most common adverse effect of SU. In a
systematic review consisting of 22 randomized controlled trials,
10.1 and 5.9% of SU treated subjects experienced hypoglycemia
as defined by blood glucose levels of ≤3.1 or ≤2.8 mmol/L,
respectively (Schopman et al., 2014). Severe hypoglycemia with
SU therapy is less common, with reported incidence of 0.8%. SU
treatment also results in weight gain of 1–3 kg (Schopman et al.,
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The CYP2C8*3 variant was
associated with less weight
gain (P = 0.02).
Bailey et al. (2010) Edema Rosiglitazone 965 GWAS GWAS rs6123045 an intronic SNP
in the NFATC2 was
significantly associated with
edema (OR 1.89 [95% CI
1.47–2.42]; P = 5.32 x
10−7)














weight gain P < 0.0003)




The A allele at 11482G>A
was associated with less
weight gain (GG, 1.33 ±
1.59 kg; GA, 0.85 ±
1.89 kg; and AA, 0.03 ±
1.46 kg; P = 0.010)
2014). Risk of hypoglycemia and weight gain may vary with age,
gender, renal function, disease progression, drug exposure, and
genetic constitution.
In this systematic review, we have included studies that
investigated association between genetic variants in genes,
CYP2C9 and ABCC8/KCNJ11, that encode CYP2C9 and
SUR1/Kir6.2 with risk of hypoglycemia (Holstein et al., 2005,
2011, 2012; Ragia et al., 2009, 2012, 2014; Gökalp et al.,
2011) (Table 4). An association between reduced function
CYP2C9∗2 and CYP2C9∗3 alleles with higher risk of SU related
hypoglycemia was reported confirming earlier functional and
pharmacokinetic data (Ragia et al., 2009; Gökalp et al., 2011).
However, another study could not confirm the findings (Holstein
et al., 2011). In the later study subjects within the control
arm that carry slow metabolizing alleles were found to be
treated with significantly lower doses than carriers of the wild
type, whereas in the group with severe hypoglycemia, the dose
was the same for all genotype groups. Another small study
suggested a possible interaction between P450 oxidoreductase
(POR) and CYP2C9 genotypes (Ragia et al., 2014), where
POR∗28 allele could mask the effect of CYP2C9∗2 allele on
sulfonylurea-induced hypoglycemia. Indeed, a bigger study
from the GoDARTS cohort confirmed this and therefore it
is worth considering CYP2C9 and POR genotypes jointly in
studies involving the pharmacogenetics of SU (Dujic et al.,
2018).
Three other studies investigated association between two
strongly linked non-synonymous polymorphisms, S1369A
(rs757110) and E23K (rs5219), in the ABCC8 and KCNJ11
genes, respectively with hypoglycemia (Sato et al., 2010; Holstein
et al., 2012; Ragia et al., 2012). None of these studies showed
statistically significant association between SU treatment and
risk of hypoglycemia suggesting these polymorphisms may not
play a major role in the etiology of hypoglycemia.
Thiazolidinediones
Thiazolidinediones are insulin sensitizers that act by increasing
the transactivation activity of Peroxisome Proliferators Activated
Receptors (PPARs). The clinically used TZDs, rosiglitazone and
pioglitazone, suffer from serious side effects. Concerns about
the cardiovascular safety of rosiglitazone due to fluid retention
led suspension in the European market and several restrictions
in the US (Woodcock et al., 2010; Shukla and Kalra, 2011).
Unlike rosiglitazone, pioglitazone did not show any risk of
cardiovascular side effects. However, concerns were raised on the
apparent risk of bladder cancer with pioglitazone and hence it
is not recommended in people with active or prior history of
bladder cancer (Shukla and Kalra, 2011). TZDs are associated
with an average of 2–4 kg weight gain in the first year of
management (Yki-Järvinen, 2004). In addition, these agents
result in peripheral edema in 4–6% (Graham et al., 2010).
This systematic review identified four articles that assessed
association between genetic variants in candidate genes and
weight gain and/or oedema after treatment with TZDs (Kang
et al., 2006; Ruaño et al., 2009; Bailey et al., 2010; Dawed
et al., 2016) (Table 5). A post-hoc analysis from the DREAM
(Diabetes REduction Assessment with ramipril and rosiglitazone
Medication) trial that consist of 4,197 participants showed higher
rate of roziglitazone-induced edema (OR= 1.89 [95% CI= 1.47–
2.42], P = 0.017) in subjects homozygous for the C allele at
rs6123045, a variant at the Nuclear Factor of Activated T-cells,
Cytoplasmic, Calcineurin-Dependent 2 (NFATC2) locus (Bailey
et al., 2010). We have previously showed association between the
CYP2C8∗3 variant with less weight gain compared to the wild
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type (P = 0.02) in the GoDARTS (Dawed et al., 2016). Another
study by Ruaño et al. investigated 384 SNPs in 87 subjects
treated with TZDs and reported significant association between
an intronic SNP, rs903361, in Adenosine A1 Receptor (ADORA1)
and BMI after correcting for multiple testing (Ruaño et al., 2009).
The A allele at Perilipin 1, PLIN 11482G>A (rs894160), was also
associated with less weight gain in Korean subjects treated with
rosiglitazone compared to the G allele (Kang et al., 2006). Given
these findings replicate in well-powered independent studies, we
could potentially identify individuals who can benefit from the
considerable therapeutic advantages of TZDs and who are least
at risk for the side effects.
DISCUSSION
This systematic review considers the adverse effects of glucose
lowering drugs and their relationship to genetic variability. It
presents the up-to-date knowledge of genetic variants that could
influence ADRs related to drugs for the management of type
2 diabetes. Comprehensive understanding of genetic variants
associated with ADRs have clinical utility in risk stratification
of patients and precision therapeutics. Although numerous
associations of genetic variants with ADR have been discovered,
replication has proven difficult. This could mainly be due to
a smaller sample which may not be sufficiently powered to
detect the desired effect, the lack of consistent phenotypic
definitions used, presence of possible drug-drug interactions, and
related comorbidities.
This systematic review suggests that at present the clinical
translation of genetic variants associated with ADR in diabetes
therapy are limited.
Inter-ethnic differences in the susceptibility to ADRs and
response to drugs are under-investigated. However, inter-ethnic
differences have long been recognized as a crucial aspect of the
genetics of variation in drug response. This could be due to
differing background frequencies of risk alleles. For example,
the frequency of 420del allele, that causes reduced OCT1
function and associated with higher odds of GI side effects of
metformin, is much higher amongst European (∼17%) than
East Asian (∼0.5%) or African (∼6%) populations (Karczewski
et al., 2020). The same is true for the loss of function variant,
CYP2C9∗3 (European∼6.7%, African∼1.3%, South Asian 1.2%)
(Karczewski et al., 2020).
It is also likely that adverse drug reactions are polygenic.
In polygenic effects, risk is conferred by combinations between
several variants each of which could have small individual
effects that are summarized as polygenic risk scores. We have
previously shown a better prediction of metformin-induced GI
intolerance by combining SNPs in the OCT1 (SLC22A1) and
PMAT (SLC29A4) (Dawed et al., 2019), pioglitazone-related
weight gain and SNPs in the SLCO1B1 and CYP2C9 (Dawed
et al., 2016). Comprehensive studies encompassing data from
hypothesis free genome-wide associations are required to identify
susceptibility loci. In addition, next generation sequencing that
allows the analysis of rare variants that have been postulated
to have larger effects are likely to reveal functionally relevant
genomic variations for ADRs.
Clinical, anthropometric, and environmental factors such as
age, sex, weight, concomitant use of other drugs was also shown
to contribute to ADRs in diabetes. Older people, women, and
concomitant use of gut metformin transporter inhibiting drugs
were previously shown to increase the likelihood of GI side effects
of metformin (Dujic et al., 2015; Dawed et al., 2019). In addition,
longer diabetes duration, impaired renal function, lower body
mass index, lower triglyceride levels and old age were identified as
major risk factors for hypoglycemia in people with type 2 diabetes
(Schloot et al., 2016).
Even though this review is comprehensive, it is subjected
to limitations. First, the studies included were heterogeneous
in design with regards to treatment, adverse effect outcomes
definitions, and population (ethnicity). The timing to measure
primary endpoint (adverse effects of oral glucose-lowering
agents) is also not uniform.
Poor adherence to treatment is a well-known phenomenon
in patients with diabetes and is associated with inadequate
glycaemic control leading to rapid disease progression and
complications (Polonsky and Henry, 2016). Moderate and severe
ADRs such as hypoglycemia and GI intolerance are previously
shown to be key contributors of poor adherence in diabetes.
In conclusion, there are few pharmacogenomic studies of
ADRs in type 2 diabetes that have been undertaken. Most of the
studies have not been externally replicated, except OCT1 and
metformin induced GI intolerance, CYP2C9 and SU-induced
hypoglycemia. In the future, well-powered pharmacogenomic
studies in T2D should collect standardized ADR data in multi-
ethnic populations.
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